Alunbrig recommended by NICE for non-small-cell lung cancer

 NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.

Read on PharmaTimes

Trajenta meets primary endpoint in CAROLINA trial

 Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk.

Read on PharmaTimes

Could AI predict survival of ovarian cancer patients?

 Researchers have created new AI machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.

Read on PharmaTimes

NICE changes its mind on Perjeta

 NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.

Read on PharmaTimes

New Academy launched to fight osteoporosis

 The Royal Osteoporosis Society has set up an academy to ultimately to find a cure for osteoporosis.

Read on PharmaTimes

1 2 3

Top of page

Industry News

NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us